Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Rink

Showing results (11-20 of 292) with videos related to

Pageof 30
Sort By:
Aktuelle Urologie|April 15, 2020
[Surgery only? Multimodal treatment for urothelial carcinoma of the bladder]Victor Schuettfort, Shahrokh F Shariat, Michael Rink
BJU International|February 4, 2020
The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancerFlorian Janisch, Michael Rink, Shahrokh F Shariat
Translational Andrology and Urology|January 13, 2017
Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?Michael Rink, Shahrokh F Shariat, Armin Soave
European Urology|March 12, 2022
Re: Christopher Soliman, Niranjan J. Sathianathen, Gianluca Giannarini, et al. There is a Need for a Universal Language in the Reporting and Grading of Complication and Intervention Events to Ensure Comparability and Improvement of Surgical Care. Eur Urol. 2022;81:440-5Mara Koelker, Michael Rink, Malte W Vetterlein
Translational Andrology and Urology|January 23, 2018
Online tools for patient counseling in bladder and kidney cancer-ready for prime time?Philipp Gild, Michael Rink, Christian P Meyer
Current Opinion in Urology|June 3, 2014
Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancerKathrin Simonis, Shahrokh F Shariat, Michael Rink, et al.
World Journal of Urology|October 28, 2018
The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladderMichael Rink, Heidi Schwarzenbach, Sabine Riethdorf, et al.
European Urology|May 8, 2020
Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder CancerMalte W Vetterlein, Philipp Gild, Margit Fisch, et al.
Current Opinion in Urology|October 14, 2017
Immunotherapy for metastatic urothelial carcinoma: status quo and the futureAndrea Necchi, Michael Rink, Patrizia Giannatempo, et al.
Current Urology Reports|May 31, 2015
Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?Armin Soave, Sabine Riethdorf, Klaus Pantel, et al.
Pageof 30

Showing results (11-20 of 292) with videos related to

Sort By:
Pageof 30
Aktuelle Urologie|April 15, 2020
[Surgery only? Multimodal treatment for urothelial carcinoma of the bladder]Victor Schuettfort, Shahrokh F Shariat, Michael Rink
BJU International|February 4, 2020
The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancerFlorian Janisch, Michael Rink, Shahrokh F Shariat
Translational Andrology and Urology|January 13, 2017
Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?Michael Rink, Shahrokh F Shariat, Armin Soave
European Urology|March 12, 2022
Re: Christopher Soliman, Niranjan J. Sathianathen, Gianluca Giannarini, et al. There is a Need for a Universal Language in the Reporting and Grading of Complication and Intervention Events to Ensure Comparability and Improvement of Surgical Care. Eur Urol. 2022;81:440-5Mara Koelker, Michael Rink, Malte W Vetterlein
Translational Andrology and Urology|January 23, 2018
Online tools for patient counseling in bladder and kidney cancer-ready for prime time?Philipp Gild, Michael Rink, Christian P Meyer
Current Opinion in Urology|June 3, 2014
Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancerKathrin Simonis, Shahrokh F Shariat, Michael Rink, et al.
World Journal of Urology|October 28, 2018
The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladderMichael Rink, Heidi Schwarzenbach, Sabine Riethdorf, et al.
European Urology|May 8, 2020
Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder CancerMalte W Vetterlein, Philipp Gild, Margit Fisch, et al.
Current Opinion in Urology|October 14, 2017
Immunotherapy for metastatic urothelial carcinoma: status quo and the futureAndrea Necchi, Michael Rink, Patrizia Giannatempo, et al.
Current Urology Reports|May 31, 2015
Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?Armin Soave, Sabine Riethdorf, Klaus Pantel, et al.
Pageof 30